Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is an adult 18 years of age or older~* Has a diagnosis of advanced illness (ie, a terminal illness such as incurable cancer or other end-stage disease)~* Has a life expectancy of at least 1 month.~* Is receiving opioids on a regular schedule (not just as-needed or rescue doses) for the control of pain or discomfort for at least 2 weeks before the first dose of study drug.~* Has constipation that is caused by opioid medications.~Exclusion Criteria:~* Has a known or suspected allergy to methylnaltrexone or other similar compounds (e.g. naltrexone or naloxone).~* Has a known or suspected mechanical gastrointestinal obstruction.~* Has any potential nonopioid cause of bowel dysfunction that might be a major contributor to the constipation.~* Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study.~* Receiving opioid antagonist or partial antagonist products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylnaltrexone (Type: EXPERIMENTAL): Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and \<62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and \< 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.

Based on this trial design, predict the completion outcome and termination type (if applicable).